161 related articles for article (PubMed ID: 1310887)
61. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
62. ras mutations and expression in head and neck squamous cell carcinomas.
Yarbrough WG; Shores C; Witsell DL; Weissler MC; Fidler ME; Gilmer TM
Laryngoscope; 1994 Nov; 104(11 Pt 1):1337-47. PubMed ID: 7968162
[TBL] [Abstract][Full Text] [Related]
63. Pathology of non-small cell lung cancer. New diagnostic approaches.
Linnoila I
Hematol Oncol Clin North Am; 1990 Dec; 4(6):1027-51. PubMed ID: 1962774
[TBL] [Abstract][Full Text] [Related]
64. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
65. Role of oncogenes and tumour suppressor genes in human lung carcinogenesis.
Harris CC; Reddel R; Pfeifer A; Iman D; McMenamin M; Trump BF; Weston A
IARC Sci Publ; 1991; (105):294-304. PubMed ID: 1855868
[TBL] [Abstract][Full Text] [Related]
66. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
[TBL] [Abstract][Full Text] [Related]
67. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
Rodenhuis S; Boerrigter L; Top B; Slebos RJ; Mooi WJ; van't Veer L; van Zandwijk N
J Clin Oncol; 1997 Jan; 15(1):285-91. PubMed ID: 8996154
[TBL] [Abstract][Full Text] [Related]
68. Amplification of oncogenes in lung carcinoma grafted in nude mice.
Chauvin C; Jacrot M; Riondel J; Brambilla E; Foote AM; Brambilla C; Benabid AL
Anticancer Res; 1989; 9(2):449-52. PubMed ID: 2568771
[TBL] [Abstract][Full Text] [Related]
69. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.
Rodenhuis S; van de Wetering ML; Mooi WJ; Evers SG; van Zandwijk N; Bos JL
N Engl J Med; 1987 Oct; 317(15):929-35. PubMed ID: 3041218
[TBL] [Abstract][Full Text] [Related]
70. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
[TBL] [Abstract][Full Text] [Related]
71. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
[TBL] [Abstract][Full Text] [Related]
72. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.
Zhang Y; Sun Y; Li Y; Fang Z; Wang R; Pan Y; Hu H; Luo X; Ye T; Li H; Wang L; Chen H; Ji H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S577-82. PubMed ID: 23775406
[TBL] [Abstract][Full Text] [Related]
73. Ha-ras oncogene product in human gastric carcinoma: correlation with invasiveness, metastasis or prognosis.
Tahara E; Yasui W; Taniyama K; Ochiai A; Yamamoto T; Nakajo S; Yamamoto M
Jpn J Cancer Res; 1986 Jun; 77(6):517-22. PubMed ID: 3089984
[TBL] [Abstract][Full Text] [Related]
74. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
Sugio K; Ishida T; Yokoyama H; Inoue T; Sugimachi K; Sasazuki T
Cancer Res; 1992 May; 52(10):2903-6. PubMed ID: 1581907
[TBL] [Abstract][Full Text] [Related]
75. [Restriction polymorphism of the proto-oncogene c-Ha-ras-1 in patients with multiple primary malignant neoplasms and non-small-cell lung cancer].
Gaspar'ian AV; Sel'chuk VIu; Iakubovskaia MG; Zborovskaia IB; Tatosian AG
Genetika; 1997 Jan; 33(1):96-100. PubMed ID: 9162692
[TBL] [Abstract][Full Text] [Related]
76. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
77. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
[TBL] [Abstract][Full Text] [Related]
78. BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion.
Shen C; Wang Y; Wei P; Du X
BMC Cancer; 2016 Aug; 16(1):670. PubMed ID: 27553041
[TBL] [Abstract][Full Text] [Related]
79. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
80. Detection of K-ras mutations in lung carcinomas: relationship to prognosis.
Keohavong P; DeMichele MA; Melacrinos AC; Landreneau RJ; Weyant RJ; Siegfried JM
Clin Cancer Res; 1996 Feb; 2(2):411-8. PubMed ID: 9816185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
